RCM
SUPN icon

Rotella Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Rotella Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,800
Closed -$159K – 214
2015
Q4 		$159K Buy
+11,800
New +$183K 0.14% 251

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Rotella Capital Management's SUPN Position: Q1 2016 in Review

Rotella Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2016, closing a stake of 11,800 shares — an estimated $159K sold.

Rotella Capital Management first reported a position in SUPN in Q4 2015 and held it in 1 quarter. The position peaked at $159K in Q4 2015. 214 funds tracked by Wall St. Rank hold SUPN as of Q1 2016.

  • Rotella Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 11,800 Supernus Pharmaceuticals shares in Q1 2016, an estimated $159K.
  • Rotella Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Rotella Capital Management's Supernus Pharmaceuticals position peaked at $159K in Q4 2015.
  • 214 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.